Remidio Innovative Solutions will spotlight India’s growing strength in health AI at the India AI Impact Summit 2026, presenting technology that is already delivering population-scale screening and measurable outcomes. The Bengaluru-based pioneer positions its platform as proof that Indian innovation can move from pilot projects to global deployment.
The company reports screening more than 16 million people across 55 countries, including over 1.3 million AI-enabled assessments. Over the past year alone, its programs helped prevent blindness for tens of thousands while slashing per-test costs dramatically, enabling governments and providers to widen coverage.
Deployments span multiple Indian states and leading institutions, demonstrating readiness for real-world adoption. Remidio’s visibility across national and state pavilions at the summit reflects strong alignment with public digital-health priorities.
In a large comparative evaluation published in The Lancet Digital Health and tested within the National Health Service, the company’s system ranked among the most balanced for accuracy and reliability across vast patient volumes.
Remidio says it is the only platform with both Indian CDSCO clearance and European CE approval capable of detecting diabetic retinopathy, glaucoma and macular degeneration in a single workflow. Compliance with ABDM, HIPAA and GDPR frameworks makes it export-ready.
The next frontier is oculomics—using retinal signals to flag systemic risks such as cardiovascular or kidney disease. By converting an eye test into a broader health gateway, Remidio aims to shift medicine toward earlier, preventive intervention.
At the summit, visitors can experience how India-built AI is moving from vision care to whole-person health intelligence.
See What’s Next in Tech With the Fast Forward Newsletter
Tweets From @varindiamag
Nothing to see here - yet
When they Tweet, their Tweets will show up here.
